Dr Chaohong Hu has been an Independent Non-executive Director of the Company since 2024. She is also a member of the Nomination Committee and  Technical Committee of the Company. She has over 20 years of experience in the development of therapeutic antibodies, antibody-drug conjugates, and vaccines. Throughout her career, she has demonstrated strong leadership and innovative capabilities, leading various research and development initiatives. Dr Hu’s expertise spans from early-stage discovery to clinical development and commercialization. She also has a proven track record of successful business development and strategic partnerships, including out-licensing and collaboration.

Dr Hu is currently Chief Operating Officer of D Biotherapeutics, LLC and an owner and principal consultant of Lakebio Consulting, LLC.  She was previously executive director and co-chief executive officer of Lepu Biopharma Co., Ltd. from 2020 to January 2024.  She was also chief executive officer and Chairman of the Board of Shanghai Miracogen Inc., a company founded by Dr Hu, focusing on the research and development, clinical study and industrialization of new drugs for targeted cancer therapy – antibody drug conjugates.  Prior to founding Shanghai Miracogen Inc., Dr Hu served as a director of the Bioassay Development and Process Analytics department at Seagen Inc.; director of Molecular Biology and Clinical Immunology department of GlaxoSmithKline plc (currently GSK plc); and research scientist and director of Molecular Biology and Clinical Immunology department of ID Biomedical Corporation.  She was also a postdoctoral fellow of the University of Washington.

Dr Hu holds a Bachelor of Science degree in biochemistry from Wuhan University and a PhD in molecular biology from Institute of Biophysics, Chinese Academy of Sciences.